Abstract: The invention belongs to the field of biotechnology. It concerns a biocatalyst, i.e. a dead or living microorganism or a polypeptide, preferably in isolated form, which exhibits acylase enzymatic activity without lipase- or esterase-activity. The biocatalyst is capable of stereoselectively hydrolysing a racemic acylamide which has an aliphatic acyl residue and which is not a derivative of a natural amino acid.

Abstract: The present invention relates to human metabotropic glutamate receptor (hmGluR) proteins, isolated nucleic acids coding therefor, host cells producing the proteins of the invention, methods for the preparation of such proteins, nucleic acids and host cells, and uses thereof.

Abstract: The current invention concerns the use of a receptor from the RZR/ROR receptor family or of a functional fragment thereof in a test of a compound for anti-autoimmune, anti-arthritic, anti-tumor, melatonin-like and/or melatonin-antagonistic activity and the production of a receptor ligand complex comprising said receptor or a functional fragment thereof and a ligand of said receptor. Described is also a method for testing compounds for said activity (screening for ligands) and the active compounds identified therewith.

Abstract: Disclosed are methods of reducing fibrosis and adhesion formation in a surgical patient wherein the AT1 receptor antagonist, the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2′(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine (valsartan) of formula or a salt thereof, in particular a pharmaceutically acceptable salt thereof, is administered to the patient. In particular, disclosed are methods of reducing pericardial fibrosis and pericardial adhesion formation which results from cardiac surgery.

Abstract: The invention relates to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension, (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, myocardial infarction and its sequelae, supraventricular and ventricular arrhythmias, atrial fibrillation or atrial flutter, atherosclerosis, angina (whether stable or ustable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, hypertension in patients with NIDDM, secondary aldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzhei

Abstract: The invention relates to novel genes for human phospholipase D (PLD2), proteins produced by the gene, variants of PLD2, antibodies to the protein, assays using the protein and antibodies, and methods of treating PLD-dependent diseases using the compositions of the invention.

Abstract: Use of a compound of formula I wherein R1 is a C1-4 alkoxy or thioalkoxy group, and R2 is a group of formula SR10 or OR10 wherein R10 is a C1-4 carboxylic or thiocarboxylic acid residue in salt, ester, free acid or activated form, or an activated form thereof, as a linker in solid phase synthesis of organic compounds, preferably of carbamates and secondary amines, and in addition are provided processes, solid phase systems and intermediates based on the compound of formula I.

Abstract: Pharmaceutical compositions and methods for the treatment of osteoporosis in mammals are disclosed. The compositions are suitable for parenteral administration and comprise Insulin-Like Growth Factor I (IGF-I) and a pharmaceutically acceptable carrier. The compositions for use in the methods may also include bone antiresorptive compounds.

Abstract: The invention provides the use of an AT1 receptor antagonist, or a pharmaceutical salt thereof, for producing a pharmaceutical preparation for the stimulation of apoptosis and for the treatment of pathological symptoms which are substantially reduced, halted or prevented by apoptosis, and also corresponding pharmaceutical preparations.

Abstract: The compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)bip henyl-4-yl-methyl]amine (valsartan) of formula ##STR1## or a salt thereof, in particular a pharmaceutically acceptable salt thereof, can be used for treating (acute and chronic) postischemic renal failure and for protecting the ischemic kidney.

Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.

Abstract: Oligonucleotides of the formula: 5'(U).sub.n -3' in which U is an identical or different radical of a natural or a synthetic nucleoside and n is a number from 2 to 200 comprising at least one structural unit of two consecutive nucleosides wherein one of the nucleotides is substituted in the 2'-position or wherein the nucleotides are substituted differently in their 2'-position and wherein the backbone is modified.

Abstract: The invention concerns a method for screening a compound which is a candidate modulator of signal response comprising the steps of; (a) incubating the compound with the PH domain of a signaling molecule which is capable of fluorescing; (b) determining the phospholipid-induced modulation in florescence of the PH domain, an alteration of the florescence in the presence of the compound being indicative of a functional interaction between the compound and the PH domain.

Abstract: The current invention describes the identification of a novel widely-expressed human and D. melanogaster serine/threonine protein kinase (designated nuclear, Dbf2-related kinase, or Ndr; previously referred to as Ndr) and the use of this kinase for the identification of agonists and antagonists. The kinase is a nuclear protein and contains a short basic peptide, KRKAETWKRNRR, responsible for the nuclear accumulation.

Abstract: The invention relates to deoxyribo- and ribo-oligonucleotides and derivatives thereof, as well as pharmaceutical preparations, therapies, diagnostics and commercial research reagents in relation to disease states which respond to modulation of the synthesis of the enzyme S-adenosylmethionine decarboxylase (SAMDC). In particular, the invention relates to antisense oligonucleotides and oligonucleotide derivatives specifically hybridizable with nucleic acids relating to (preferably human) SAMDC. These oligonucleotides and their derivatives have been found to modulate the synthesis of SAMDC in cells.

Abstract: A method is disclosed for iontophoretically removing any compound that is capable of causing skin irritation or other harmful effects. More specifically, a bipolar iontophoretic transdermal delivery method is disclosed that includes a reversal phase for controlling the iontophoretic transdermal delivery of pharmaceutical compounds while reducing or eliminating skin irritation and terminating the pharmacological or toxicological effects in skin of drugs/cosmetics/active ingredients which form a drug depot in the skin after passive or iontophoretic application.

Abstract: Cyclopeptolides of formula (I), wherein A, B, R.sub.1 Leu, Leu, C, X and Y are as defined, are inhibitors of adhesion molecule, expression and inhibitors of TNF release and are thus useful for treatment of inflammatory and other diseases which involve increased levels of adhesion molecule expression and/or are mediated by TNF.

Abstract: The current invention describes the identification of a novel widely-expressed human and D. melanogaster serine/threonine protein kinase (designated nuclear, Dbf2-related kinase, or Ndr; previously referred to as Ndr) and the use of this kinase for the identification of agonists and antagonists. The kinase is a nuclear protein and contains a short basic peptide, KRKAETWKRNRR, responsible for the nuclear accumulation.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are each independently of the other hydrogen or a protecting group, orR.sub.1 has those meanings andR.sub.2 is a radical forming a phosphorus-containing nucleotide bridge group;B is a purine or pyrimidine radical or an analogue thereof; andR.sub.3 is OH, or F, and oligonucleotides that comprise those nucleosides are described.

Abstract: The subject invention is related to human MMP-8alt genes and gene products and their differential expression when comparing a patient with a disease state to a control. A further aspect of the invention concerns compounds which antagonize the biological activity of MMP-8alt protein and methods for identifying these compounds. Another aspect of the present invention concerns pharmaceutical compositions comprising such compounds for the treatment of arthritis, cancer, and disease caused by cellular apoptosis including but not limited to Parkinson's disease, Alzheimer's disease and Huntington's chorea.